179 related articles for article (PubMed ID: 34151251)
41. Bottom-Up and Top-Down Approaches to Explore Sodium Dodecyl Sulfate and Soluplus on the Crystallization Inhibition and Dissolution of Felodipine Extrudates.
Chen J; Chen Y; Huang W; Wang H; Du Y; Xiong S
J Pharm Sci; 2018 Sep; 107(9):2366-2376. PubMed ID: 29738699
[TBL] [Abstract][Full Text] [Related]
42. Investigation of Ethylene Oxide-co-propylene Oxide for Dissolution Enhancement of Hot-Melt Extruded Solid Dispersions.
Hurley D; Potter CB; Walker GM; Higginbotham CL
J Pharm Sci; 2018 May; 107(5):1372-1382. PubMed ID: 29410037
[TBL] [Abstract][Full Text] [Related]
43. Phase Behavior of Ritonavir Amorphous Solid Dispersions during Hydration and Dissolution.
Purohit HS; Taylor LS
Pharm Res; 2017 Dec; 34(12):2842-2861. PubMed ID: 28956218
[TBL] [Abstract][Full Text] [Related]
44. Solid dispersion of carbamazepine in PVP K30 by conventional solvent evaporation and supercritical methods.
Sethia S; Squillante E
Int J Pharm; 2004 Mar; 272(1-2):1-10. PubMed ID: 15019063
[TBL] [Abstract][Full Text] [Related]
45. A Mechanistic Model for Predicting the Physical Stability of Amorphous Solid Dispersions.
Ojo AT; Lee PI
J Pharm Sci; 2021 Apr; 110(4):1495-1512. PubMed ID: 32818440
[TBL] [Abstract][Full Text] [Related]
46. Phase behavior of poly(vinylpyrrolidone) containing amorphous solid dispersions in the presence of moisture.
Rumondor AC; Marsac PJ; Stanford LA; Taylor LS
Mol Pharm; 2009; 6(5):1492-505. PubMed ID: 19634917
[TBL] [Abstract][Full Text] [Related]
47. Enhanced kinetic solubility profiles of indomethacin amorphous solid dispersions in poly(2-hydroxyethyl methacrylate) hydrogels.
Sun DD; Ju TC; Lee PI
Eur J Pharm Biopharm; 2012 May; 81(1):149-58. PubMed ID: 22233548
[TBL] [Abstract][Full Text] [Related]
48. Evaluate the ability of PVP to inhibit crystallization of amorphous solid dispersions by density functional theory and experimental verify.
Wang B; Wang D; Zhao S; Huang X; Zhang J; Lv Y; Liu X; Lv G; Ma X
Eur J Pharm Sci; 2017 Jan; 96():45-52. PubMed ID: 27568852
[TBL] [Abstract][Full Text] [Related]
49. On the inherent properties of Soluplus and its application in ibuprofen solid dispersions generated by microwave-quench cooling technology.
Shi NQ; Lai HW; Zhang Y; Feng B; Xiao X; Zhang HM; Li ZQ; Qi XR
Pharm Dev Technol; 2018 Jul; 23(6):573-586. PubMed ID: 27824281
[TBL] [Abstract][Full Text] [Related]
50. Investigation into the Solid-State Properties and Dissolution Profile of Spray-Dried Ternary Amorphous Solid Dispersions: A Rational Step toward the Design and Development of a Multicomponent Amorphous System.
Baghel S; Cathcart H; O'Reilly NJ
Mol Pharm; 2018 Sep; 15(9):3796-3812. PubMed ID: 30020788
[TBL] [Abstract][Full Text] [Related]
51. Utilizing Drug Amorphous Solid Dispersions for the Preparation of Dronedarone per os Formulations.
Kapourani A; Manioudaki AE; Kontogiannopoulos KN; Barmpalexis P
Polymers (Basel); 2023 Nov; 15(21):. PubMed ID: 37959973
[TBL] [Abstract][Full Text] [Related]
52. Initial Drug Dissolution from Amorphous Solid Dispersions Controlled by Polymer Dissolution and Drug-Polymer Interaction.
Chen Y; Wang S; Wang S; Liu C; Su C; Hageman M; Hussain M; Haskell R; Stefanski K; Qian F
Pharm Res; 2016 Oct; 33(10):2445-58. PubMed ID: 27283830
[TBL] [Abstract][Full Text] [Related]
53. Amorphous Solid Dispersions Containing Residual Crystallinity: Competition Between Dissolution and Matrix Crystallization.
Moseson DE; Corum ID; Lust A; Altman KJ; Hiew TN; Eren A; Nagy ZK; Taylor LS
AAPS J; 2021 May; 23(4):69. PubMed ID: 34002256
[TBL] [Abstract][Full Text] [Related]
54. Reactive Melt Extrusion To Improve the Dissolution Performance and Physical Stability of Naproxen Amorphous Solid Dispersions.
Liu X; Zhou L; Zhang F
Mol Pharm; 2017 Mar; 14(3):658-673. PubMed ID: 28135108
[TBL] [Abstract][Full Text] [Related]
55. Elucidating the effect of crystallization on drug release from amorphous solid dispersions in soluble and insoluble carriers.
Ojo AT; Ma C; Lee PI
Int J Pharm; 2020 Dec; 591():120005. PubMed ID: 33132149
[TBL] [Abstract][Full Text] [Related]
56. Impact of Polymer Type on Thermal Degradation of Amorphous Solid Dispersions Containing Ritonavir.
Alvarenga BR; Moseson DE; Carneiro RL; Taylor LS
Mol Pharm; 2022 Jan; 19(1):332-344. PubMed ID: 34910485
[TBL] [Abstract][Full Text] [Related]
57. Free flowing solid dispersions of the anti-HIV drug UC 781 with Poloxamer 407 and a maximum amount of TPGS 1000: investigating the relationship between physicochemical characteristics and dissolution behaviour.
Goddeeris C; Van den Mooter G
Eur J Pharm Sci; 2008 Sep; 35(1-2):104-13. PubMed ID: 18644442
[TBL] [Abstract][Full Text] [Related]
58. Understanding the Effect of Nucleation in Amorphous Solid Dispersions through Time-Temperature Transformation.
Lalge R; Kumar NSK; Suryanarayanan R
Mol Pharm; 2023 Aug; 20(8):4196-4209. PubMed ID: 37358932
[TBL] [Abstract][Full Text] [Related]
59. Molecular dynamics simulation of amorphous indomethacin-poly(vinylpyrrolidone) glasses: solubility and hydrogen bonding interactions.
Xiang TX; Anderson BD
J Pharm Sci; 2013 Mar; 102(3):876-91. PubMed ID: 23280486
[TBL] [Abstract][Full Text] [Related]
60. Hot-melt extruded hydroxypropyl methylcellulose acetate succinate based amorphous solid dispersions: Impact of polymeric combinations on supersaturation kinetics and dissolution performance.
Butreddy A; Sarabu S; Almutairi M; Ajjarapu S; Kolimi P; Bandari S; Repka MA
Int J Pharm; 2022 Mar; 615():121471. PubMed ID: 35041915
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
